NCT00002336

Brief Summary

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts \<= 100 cells/mm3.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 1992

Typical duration for not_applicable

Geographic Reach
1 country

22 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1992

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 1994

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 1994

Completed
5 years until next milestone

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

January 16, 2015

Status Verified

February 1, 2009

Enrollment Period

2 years

First QC Date

November 2, 1999

Last Update Submit

January 15, 2015

Conditions

Keywords

Mycobacterium avium-intracellular InfectionAcquired Immunodeficiency SyndromeClarithromycin

Interventions

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have:
  • HIV infection.
  • CD4 count \<= 100 cells/mm3.
  • No evidence of MAC.
  • Life expectancy of at least 6 months.

You may not qualify if:

  • Concurrent Medication:
  • Excluded:
  • Certain restricted drugs (details not available).
  • Patients with the following prior conditions are excluded:
  • History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

Univ of Arizona / Health Science Ctr

Tucson, Arizona, 85724, United States

Location

California Med Research Group

Fresno, California, 93726, United States

Location

HIV Research Group

San Diego, California, 92102, United States

Location

Saint Francis Mem Hosp

San Francisco, California, 94109, United States

Location

Kaiser Permanente Med Ctr

San Francisco, California, 94115, United States

Location

Santa Clara Valley Med Ctr

San Jose, California, 951282699, United States

Location

TheraFirst Med Ctrs Inc

Fort Lauderdale, Florida, 33308, United States

Location

Dr Nelson Zide

Hollywood, Florida, 33021, United States

Location

Infectious Disease Research Institute Inc

Tampa, Florida, 33614, United States

Location

Indiana Univ Hosp

Indianapolis, Indiana, 46202, United States

Location

Saint Vincent's Hosp and Med Ctr

New York, New York, 10011, United States

Location

SUNY / Health Sciences Ctr at Syracuse

Syracuse, New York, 13210, United States

Location

New York Med College / Westchester County Med Ctr

Valhalla, New York, 10595, United States

Location

Nalle Clinic

Charlotte, North Carolina, 28207, United States

Location

Westover Heights Clinic

Portland, Oregon, 97210, United States

Location

Univ of Tennessee

Memphis, Tennessee, 38163, United States

Location

Vanderbilt Univ

Nashville, Tennessee, 37212, United States

Location

Univ of Texas Southwestern Med Ctr of Dallas

Dallas, Texas, 75235, United States

Location

Houston Veterans Administration Med Ctr

Houston, Texas, 77030, United States

Location

Audie L Murphy Veterans Administration Hosp

San Antonio, Texas, 78284, United States

Location

Salem Veterans Administration Med Ctr

Salem, Virginia, 24153, United States

Location

Dr Alan D Tice / Infections Ltd

Tacoma, Washington, 98405, United States

Location

Related Publications (1)

  • Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996 Aug 8;335(6):384-91. doi: 10.1056/NEJM199608083350603.

    PMID: 8663871BACKGROUND

MeSH Terms

Conditions

HIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

Clarithromycin

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

ErythromycinMacrolidesPolyketidesLactonesOrganic Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Study Start

November 1, 1992

Primary Completion

November 1, 1994

Study Completion

November 1, 1994

Last Updated

January 16, 2015

Record last verified: 2009-02

Locations